Northwest hopes to secure more funding in first quarter
This article was originally published in Scrip
Northwest Biotherapeutics hopes to secure more funding by the end of this quarter after it received $500,000 loan last month. The funding, from Toucan Partners, should finance its operations until the end of this month. The cancer-focused company has been facing financial difficulties since the latter half of last year and needs more cash to fund future clinical trials and other operating activities.